StreetAlpha.app
Home › Stocks › BEAM

Beam Therapeutics Inc. (BEAM)

Healthcare
$20.90
▼ −0.19%
LAST CLOSE · NOV 20

Beam Therapeutics develops gene editing medicines that change single DNA bases to treat serious diseases. It last closed at $20.90 on Nov 20, down 0.19% on the day. The next earnings report for BEAM is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, BEAM reported EPS of -$1.28 on revenue of $307,000, with revenue down 96.8% from a year ago. Over its last 8 reports the stock moved an average of 9.7% the session after earnings. Over the last 12 months BEAM insiders bought $0 of stock on the open market and sold $19.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is BEAM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BEAM.

Key Stats

Last 12 months
Results
Revenue
$146.6M
+163.3% vs a year ago
Net income
−$108.4M
−73.9% margin
EPS (diluted)
−$0.88
Free cash flow
−$398.2M
−271.6% margin
Valuation
Market cap
$2.2B
103.5M shares
P/E
–
No P/E while losing money
Price to sales
14.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$213.3M
At Sep 30
Debt
$100.4M
At Sep 30
Shareholder equity
$952.7M
Shares outstanding
103.5M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $51.8M$51.8MFY2021FY2022: $60.9M$60.9MFY2022FY2023: $377.7M$377.7MFY2023FY2024: $63.5M$63.5MFY2024FY2025: $139.7M$139.7MFY2025

From BEAM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$1.28
Quarter ended Sep 2026
Year ago EPS
-$1.10
Same quarter last year
Revenue
$307,000
−96.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.09Dec '24Mar 2025: -$1.23Mar '25Jun 2025: -$1.00Jun '25Sep 2025: -$1.10Sep '25Dec 2025: $2.50Dec '25Mar 2026: -$0.91Mar '26Jun 2026: -$1.18Jun '26Sep 2026: -$1.28Sep '26Latest -$1.28
Revenue by quarter
Dec 2024: $30.1MDec '24Mar 2025: $7.5MMar '25Jun 2025: $8.5MJun '25Sep 2025: $9.7MSep '25Dec 2025: $114.1MDec '25Mar 2026: $31.7MMar '26Jun 2026: $490,000Jun '26Sep 2026: $307,000Sep '26Latest $307,000
How BEAM moved after its last 8 reports
Average move the session after a report ±9.7%
Nov 3, 2026Time not announced+1.8%
Aug 4, 2026Time not announced+9.4%
May 7, 2026Time not announced−2.7%
Feb 24, 2026Time not announced+14.0%
Jan 12, 2026Time not announced+22.3%
Nov 4, 2025Time not announced−6.2%
Aug 5, 2025Time not announced−2.2%
May 6, 2025Time not announced−19.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BEAMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BEAM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BEAM

Technical Analysis

BEAM · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 18% below its 20 day and 18% below its 50 day average. It is 33% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $20.26, and the nearest resistance the Pivot at $21.18.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.2%/day
Key levels
$38.2652 week high+83.1%
$27.72200 day average+32.6%
$26.62100 day average+27.4%
$25.29Swing high (Oct 22)+21.0%
$24.7520 day average+18.4%
$24.6350 day average+17.8%
$21.82Pivot R1+4.4%
$21.18Pivot+1.3%
$20.90Last close
$20.26Pivot S1−3.1%
$20.2352 week low−3.2%
Indicators
RSI (14)35.86Weak, oversold below 30Neutral
MACD-1.20Below its signal lineBearish
Stochastic6.1Near the bottom of its rangeOversold
ADX (14)20.4Weak trend
Williams %R-93.9Oversold below −80, overbought above −20Oversold
CCI (20)-114.5Oversold below −100, overbought above 100Oversold
Rate of change−20.9%Change over 10 sessionsBearish
ATR (14)$1.72Typical daily range, 8.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BEAM

What happened before

See how BEAM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BEAM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BEAM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BEAMHow many large options trades hit BEAM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BEAM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●137 buying vs 127 selling
  • ▲Held by funds +3.0 pts
  • ▼Funds holding -14
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding264278−5.0%
In funds' top 1023−33.3%
Held by funds108.7%105.7%+3.0 pts
New / increased37 / 10056 / 93−8.1%
Reduced / sold out78 / 4976 / 31+18.7%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BEAM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BEAM Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$19.7M20 sales · 7 insiders
49% of the selling was under pre-arranged trading plans.
2025-12 sold $205K2026-01 sold $2.4M2026-02 sold $1.1M2026-03 sold $1.1M2026-04 sold $1.4M2026-06 sold $11.8M2026-07 sold $429K2026-10 sold $1.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 16John M. EvansCEOSale plan50,000$23.77$1.2M
Oct 1Bethany J CavanaghSVP, Finance and TreasurerSale plan187$24.41$5K
Jul 27Amy SimonChief Medical OfficerSale plan16,667$25.74$429K
Jun 30Amy SimonChief Medical OfficerSale plan373$34.73$13K
Jun 30John M. EvansCEOSale plan50,000$34.90$1.7M
Jun 26Fmr LLC10% ownerSale284,860$35.24$10.0M
Every insider buy and sale for BEAM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BEAM insider trades →

From SEC Form 4 filings by BEAM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BEAM is in one of them and how their past BEAM trades turned out.

BEAM in the AI portfolios
Loading…

BEAM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BEAM in an article yet. Here's the latest on the wider market.

BEAM in the news

About Beam Therapeutics

Beam Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that develops gene editing medicines for patients with serious diseases. Its main approach is base editing, which changes a single DNA letter without cutting both strands of the DNA. Its lead programs target sickle cell disease and certain inherited liver and metabolic disorders. The company also has its own manufacturing capabilities for these therapies.

Headquarters
Cambridge, MA